DelveInsight’s, “Head and Neck Cancer Pipeline Insight 2024” report provides comprehensive insights about 80+ companies and ...
Follow today’s news live. What we learned, 22 September 2024 06:56 With that we’re wrapping up the blog. Before ...
Circle Pharma, Inc., a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, today announced two executive ...
GSK has turned to Brooke Shields to get the message out about shingles vaccination. The drugmaker has worked with the model and actor to talk to female celebrities and patients aged 50 years and ...
This summer, GSK cut its yearly vaccine sales projection on the back of a narrowed recommendation for adult respiratory syncytial virus (RSV) vaccines from the Centers for Disease Control and ...
Large pharma companies also face risks. Eli Lilly has tapped WuXi Apptec to produce some of the ingredients in its blockbuster GLP-1 obesity medications, while GSK inked a licensing deal potentially ...
The College of Natural Sciences welcomed more than a dozen new tenured and tenure-track faculty members in 2024.
GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...
GSK licensed the drug from long-standing partner Ionis as part of a two-drug deal in 2019, paying $25 million upfront with milestone payments taking the value of the deal up to $262 million.
The FDA has started a review of GSK’s five-in-one meningococcal vaccine, cueing up a decision in mid-February next year, as it tries to chase down a rival candidate from Pfizer cleared last year.